Asahi Kasei Therapeutics received FDA approval for Hovilpri, a new oral treatment for herpes simplex virus lesions, after acquiring the program in an approximately $1 billion deal earlier this year. The approval adds a new option to the HSV treatment landscape and underscores how late-stage acquisition targets can accelerate time-to-market.